A recent study in Nature Medicine pinpoints sources of ozone pollution and its deadly health impacts across Europe, highlighting the need for coordinated international efforts to reduce ozone levels and related mortality rates.
MindMed’s Phase 2b Compound MM-120 Shows Promise In Treating Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company dedicated to pioneering innovative treatments for brain health disorders, has announced topline outcomes